Skip to main content

Advertisement

Log in

Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Patients admitted to hospital with acute severe ulcerative colitis have a short-term in-hospital colectomy rate of 30%. The Oxford criteria state that if the CRP is greater than 45 mg/l or there are more than eight bowel movements in 24 h at day 3 of intravenous corticosteroids, there is an 85% risk of an in-hospital colectomy.

Aim

The aim of this study was to determine whether this high rate of colectomy continues to be accurate in this medically refractory patient population.

Methods

We performed a retrospective chart review of 80 patients admitted to a tertiary hospital between 2013 and 2017 with acute severe ulcerative colitis.

Results

Sixteen (20%) patients required an in-hospital colectomy. Of the 33 patients that fulfilled the Oxford criteria, 12 (36%) patients required a colectomy during admission. Only four (9.5%) patients who did not fulfill the Oxford criteria required a colectomy during admission. Twenty-two patients that had fulfilled the Oxford criteria received infliximab as second-line medical therapy.

Conclusion

In a patient population that fulfilled the Oxford criteria, the in-hospital colectomy rate has reduced from 85% in 1996 to 36% in 2017. These results should be considered when discussing with patients the opportunity to commence infliximab or cyclosporine as second-line medical therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299–315.

    Article  CAS  Google Scholar 

  2. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179–194.

    Article  CAS  Google Scholar 

  3. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4:431–437.

    Article  Google Scholar 

  4. Ananthakrishnan AN, McGinley EL, Binion DG, et al. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–276.

    Article  Google Scholar 

  5. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. BMJ. 1954;2:375–378.

    Article  CAS  Google Scholar 

  6. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.

    Article  CAS  Google Scholar 

  7. Parragi L, Fournier N, Zeitz J, et al. Colectomy rates in ulcerative colitis are low and decreasing: 10-year follow-up data from the Swiss IBD Cohort study. J Crohns Colitis. 2018;12:811–818.

    Article  Google Scholar 

  8. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–515.

    Article  Google Scholar 

  9. Gallagher ND, Goulston SJM, Wyndham N, et al. The management of fulminant ulcerative colitis. Gut. 1962;3:306–311.

    Article  CAS  Google Scholar 

  10. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–910.

    Article  CAS  Google Scholar 

  11. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6:1112–1116.

    Article  CAS  Google Scholar 

  12. Kassim O, Micic D, Christensen B, et al. P454 Can calcineurin inhibitors induce a durable remission that is maintained with vedolizumab in IBD? J Crohns Colitis. 2017;11:S309.

    Article  Google Scholar 

  13. Halmos EP, Biesiekierski JR, Newnham ED, et al. Inaccuracy of patient-reported descriptions of and satisfaction with bowel actions in irritable bowel syndrome. Neurogastroenterol Motil. 2018. https://doi.org/10.1111/nmo.13187.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

AM was involved in analysis and interpretation of data and drafting of the manuscript. BB was involved in the critical revision of the manuscript for important intellectual content.

Corresponding author

Correspondence to Alice C. Moore.

Ethics declarations

Conflict of interest

Brian Bressler is an advisor and speaker for Shire, Ferring, Janssen, Abbvie, Takeda and Actavis and an advisor for Amgen, Pendopharm, Genentech, Celltrion, Pfizer, Allergan and Protagonist. Research support is provided by Janssen, Abbvie, GSK, BMS, Amgen, Genentech, Merck, RedHill Biopharm, BI, Qu Biologic, Celgene, and Alvine. He has stock options with Qu Biologic. There are no financial disclosures or other relevant conflicts of interest for any other author.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moore, A.C., Bressler, B. Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates. Dig Dis Sci 65, 576–580 (2020). https://doi.org/10.1007/s10620-019-05668-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05668-6

Keywords

Navigation